Study Summary
This trialwill study gene therapy to help boys with Duchenne Muscular Dystrophy (DMD) with safety and muscle strength. No randomization, open to all.
- Duchenne Muscular Dystrophy
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
0 Primary · 12 Secondary · Reporting Duration: Through 5 years
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
1 Treatment Group
PF-06939926
1 of 1
Experimental Treatment
10 Total Participants · 1 Treatment Group
Primary Treatment: PF-06939926 · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 2 - 3 · Male Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is enrollment open to those over 20 years of age for this clinical experiment?
"This clinical trial's eligibility criteria necessitates that participants are aged between 2 and 3. Individuals who fall below the age of consent can take part in 59 separate studies, while those above 65 can enrol into 50 different trials." - Anonymous Online Contributor
Am I able to join this clinical investigation?
"Applicants aged 2 - 3 with a formally diagnosed case of becker muscular dystrophy are currently being sought for this study. Critically, those hoping to join must have prior genetic testing certifying their diagnosis." - Anonymous Online Contributor
Is this experiment actively accepting new participants?
"According to clinicaltrials.gov, the recruitment period for this medical trial is ongoing; it first went live on 8th August 2022 and was recently revised on 12th December 2022." - Anonymous Online Contributor
Has the FDA authorized PF-06939926 for general use?
"We at Power have determined that the safety of PF-06939926 can be rated a 2, as this is a Phase 2 clinical trial and while there exists some evidence demonstrating its security, no data has yet been provided suggesting efficacy." - Anonymous Online Contributor
How many participants have volunteered for this research experiment?
"Affirmative. Clinicaltrials.gov shows that this medical study, which was launched on August 8th 2022, is actively enrolling patients. At six different trial sites across the nation, 10 participants must be recruited for the clinical investigation to progress as planned." - Anonymous Online Contributor